GB2380196A - Transgenic animals with mutant human amyloid precursor protein sequences - Google Patents
Transgenic animals with mutant human amyloid precursor protein sequences Download PDFInfo
- Publication number
- GB2380196A GB2380196A GB0219386A GB0219386A GB2380196A GB 2380196 A GB2380196 A GB 2380196A GB 0219386 A GB0219386 A GB 0219386A GB 0219386 A GB0219386 A GB 0219386A GB 2380196 A GB2380196 A GB 2380196A
- Authority
- GB
- United Kingdom
- Prior art keywords
- human
- app
- cell
- transgenic
- human animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 63
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 title claims abstract description 21
- 241001465754 Metazoa Species 0.000 title claims description 22
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical group C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title description 52
- 210000004556 brain Anatomy 0.000 claims abstract description 30
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 21
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 21
- 239000002157 polynucleotide Substances 0.000 claims abstract description 21
- 102000046783 human APP Human genes 0.000 claims abstract description 20
- 108091026890 Coding region Proteins 0.000 claims abstract description 17
- 230000035772 mutation Effects 0.000 claims abstract description 11
- 102220269180 rs186659284 Human genes 0.000 claims abstract description 8
- 102220552925 Fidgetin-like protein 1_V46P_mutation Human genes 0.000 claims abstract description 6
- 102220597401 G0/G1 switch protein 2_V46A_mutation Human genes 0.000 claims abstract description 6
- 102220502428 Polyadenylate-binding protein 2_V46W_mutation Human genes 0.000 claims abstract description 6
- 102220047655 rs587783134 Human genes 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 5
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 claims abstract 5
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 claims abstract 5
- 229910052791 calcium Inorganic materials 0.000 claims abstract 5
- 239000011575 calcium Substances 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 25
- 108020004414 DNA Proteins 0.000 claims description 20
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000001413 cellular effect Effects 0.000 claims description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 2
- 210000001320 hippocampus Anatomy 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims 4
- 210000004958 brain cell Anatomy 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 210000000287 oocyte Anatomy 0.000 claims 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract description 3
- 102220067614 rs141174358 Human genes 0.000 abstract description 3
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 51
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 51
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 51
- 108700019146 Transgenes Proteins 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 208000037259 Amyloid Plaque Diseases 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100021257 Beta-secretase 1 Human genes 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 101710150192 Beta-secretase 1 Proteins 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- 102000015499 Presenilins Human genes 0.000 description 4
- 108010050254 Presenilins Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 3
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- -1 Aspartyl Chemical group 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 101100491373 Mus musculus Aplp2 gene Proteins 0.000 description 2
- 101100231531 Mus musculus Hmgcr gene Proteins 0.000 description 2
- 101001018320 Mus musculus Myelin basic protein Proteins 0.000 description 2
- 101100298534 Mus musculus Prnp gene Proteins 0.000 description 2
- 101000766305 Mus musculus Serotransferrin Proteins 0.000 description 2
- 101100260568 Mus musculus Thy1 gene Proteins 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 description 2
- 101000821095 Rattus norvegicus Synapsin-1 Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 102000055647 human CSF2RB Human genes 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229940124606 potential therapeutic agent Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101100055496 Arabidopsis thaliana APP2 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001144416 Picornavirales Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 101100016250 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GYL1 gene Proteins 0.000 description 1
- 101710187074 Serine proteinase inhibitor Proteins 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 101150080892 asp2 gene Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012143 dye reagent concentrate Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 102000044297 human BACE1 Human genes 0.000 description 1
- 102000045409 human FMR1 Human genes 0.000 description 1
- 102000055060 human PSEN1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a recombinant DNA construct comprising a comprising a coding sequence encoding human APP with a mutation selected from V46F, V46I, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N, and V46Q and a brain-specific calcium calmodulin kinase promoter sequence which is operably linked to the coding sequence. Further provided is a transgenic non-human animal whose genome incorporates a polynucleotide comprising a coding sequence which encodes the human APP protein with a mutation selected from V46F, V46I, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N, and V46Q wherein said coding sequence is operably linked to a brain-specific calcium calmodulin kinase II promoter sequence. (Numbering is based upon the APP C-terminal fragment A4CT (C99), and corresponds to Val 717 of APP 770 ).
Description
<Desc/Clms Page number 1>
COMPOUNDS
This invention relates to transgenic animals and their use as models of Alzheimer's disease.
The main protein component of the amyloid plaques found in the brain of Alzheimer's disease (AD) patients is Ap, a 4 kDa peptide consisting of mainly forty and forty-two residues (Ap) o, Api) being derived from the amyloid precursor protein (APP). APP can exist in multiple forms generated by alternative mRNA splicing. The first form of APP identified by Kang, J., et al., (ref 1) from a foetal brain cDNA library contained 695 amino acids (so-called APP695). This includes a 17 residue signal peptide sequence for transport of the protein into the endoplasmic reticulum. Subsequently, a number of slightly longer cDNA clones were isolated by other workers. The 751 amino acid APP sequence (APP751) described by Ponte, P. , et al., (ref 2) contained an additional 57-amino acid insert encoding a Kunitz-type serine proteinase inhibitor (KPI). Kitaguchi, N. , et al., (ref 3) identified another precursor of 770 ammo acids (APP770) with both the KPI sequence and an additional 19 amino acid insert. These isoforms of APP arise as a result of alternative splicing of exons 7 and 8 during transcription of the APP gene.
Additional isoforms generated by alternative splicing of exon 15 have also been detected (ref 4).
Human APP herein refers to all isoforms including the 695 form and A4CT.
APP can be cleaved at the N-terminus of Ass by an enzyme called ss-secretase generating
a soluble APP and the C-terminal fragment A4CT (C99). This 99 residue long membrane protein A4CT (ref. 5) which is the direct precursor for Ap contains the entire Ap domain, the membrane domain and the cytoplasmic tail of APP. Alternative processing of APP in a post-Golgi- compartment by a protease termed a-secretase leads to the cleavage of APP within the Ap domain yielding secretory APP and the transmembrane fragment p3CT which is the direct precursor for p3.
Both C-terminal fragments of APP, A4CT and p3CT, are cleaved within the membrane domain by a y-cleavage activity, thereby releasing Ass and p3 into the medium (refs. 6,7). In cells expressing wild type APP the site of y-cleavage is mainly the peptide bond Val (40)-Ile (41) of A4CT and to a minor extent the bond Ala (42)-Thr (43). In cells expressing APP with the Familial AD linked mutations at Val 717 (based on APPyyo, Val 46 of A4CT) an increased y-cleavage occurs behind Val (42), thus producing larger amounts of AP142 (ref 8).
A number of Familial AD linked mutations have been observed, namely V46F, V461 and V46G (numbering relative to A4CT).
Transgenic mice expressing A4CT have been produced using the human APP promoter (ref. 9), the human thy-1 promoter (ref. 10) and the JC viral early region promoter (ref. 11).
<Desc/Clms Page number 2>
Transgenic mice have also been produced expressing amino acids 591-695 of APP695 (Cterminal 105 amino acids of APP) under control of the human neurofilament NF-L transcriptional regulatory sequences (ref. 12). Numerous promoters have been used in conjunction with the full length APP cDNA (refs. 13-18). Generation of transgenic mammals bearing APP derived DNA sequences are also described in W093/14200 (TSI Corporation),
W091/19810 (California Biotechnology Inc), W093/02189 (University of Calfornia), W089/00689, W092/06187 (The Upjohn Company), EP0451700 (Miles Inc.), W092/13069 (Imperial College of Science Technology and Medicine) and W089/06689 (McClean Hospital Corporation). These include other APP mutations, namely V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N and V46Q.
However in not all the above cases described to date has the nature of the APPimmunoreactive deposits resembled the clinical situation and, with the exception of the models described in references 14,16 and 18, such transgenic animals have not been found to be faithful model systems for the amyloid deposits characteristic of Alzheimer's disease. Results obtained depend upon the source of the promoter and the protein coding sequence used. We have found that the use of a specific neuronal promoter will increase the possibility of the development of pathology that resembles the clinical situation. W098/03643 and refs. 19 and 20 disclose constructs comprising mutant human APP or A4CT DNA sequences.
The mouse CaM-kmase-II promoter is described in ref. 21 and 22.
Transgenic animals of the invention may develop amyloid plaques and are therefore useful as a model of Alzhiemer's disease and other neurodegenerative disorders.
The present invention relies on the use of a nucleic acid construct to generate a transgenic animal model for screening agents for potential use in the treatment of neurological disorders, in particular Alzheimers disease. The construct comprises a polynucleotide sequence encoding the human APP or A4CT protein with a mutation selected from V46F, V46I, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N, and V46Q (numbering relative to A4CT), operatively linked to a mouse CaM-K-II promoter. Such polynucleotide sequence is herein termed a human APP encoding polynucleotide. In a preferred embodiment, the nucleic acid construct further comprises a Internal Ribosomal Entry Site (IRES) downstream (3') of the nucleotide encoding the human APP protein, and a nucleic acid sequence encoding a reporter gene downstream of the IRES. This type of construct is termed bi-cistronic, and enables separate expression of both the human APP protein, and the reporter protein. The reporter protein may be, for example, luciferase, green fluorescent protein or derivatives thereof, or ss galactosidase, but preferably it is p galactosidase. The advantage of such a construct is that it enables one to monitor human APP2 expression, by monitoring expression of the reporter gene.
<Desc/Clms Page number 3>
It will be understood that references herein to A4CT, API-42 and Apt-40 include all N-and C-terminal variants produced by alternative cleavage during processing.
In a preferred aspect the mutation in the human APP or A4CT transgene is V46F. In a further preferred aspect the DNA sequence is full length human APP, more preferably APP695, preferably without the signal sequence.
In one embodiment the human APP encoding polynucleotide is carried on a construct which further encodes the APP signal sequence (APP residues 1 to 17) immediately upstream (5') of the APP or A4CT DNA sequence. Hydrophobic residue inserts such as Leu, Glu or Met promote processing of A4CT to Ap and may be be included between the signal peptide and A4CT coding regions and will remain attached to the processed A4CT.
A"transgene"comprises a polynucleotide, isolated from nature, which has been manipulated in-vitro and which can be subsequently introduced into the genome of the same or a different species in either the native or modified forms, such that it is stably and heritably maintained in that genome. The polynucleotide preferably encodes a protein of interest, and is generally operatively linked to a regulatory sequence. The term transgene is herein used to refer to the polynucleotide and the regulatory sequences to which it is operably linked. The transgene may further comprise other polynucleotides which encode, for example, reporter genes in order to monitor expression of the transgene. An organism into which a transgene has been introduced is termed a"transgenic organism". A"transgenic construct"is a vector construct comprising the transgene.
The term"transgenic DNA"as used herein refers to the polynucleotide comprised within the transgene, which polynucleotide encodes the protein of interest.
The assembly of the transgenic construct follows standard cloning techniques, that are well known in the art (for example see Sambrook et al, (23) ). The human APP encoding polynucleotide may consist of cDNA or genomic DNA. If it is cDNA, the cDNA to be overexpressed can be prepared from a mRNA extracted from a relevant tissue, preferably a tissue in which the APP protein is known to be expressed, or alternatively can be extracted by probing a human cDNA library. The transgenic DNA, along with the CaMKII promoter and any other desired components such as artificial introns, the IRES, or a reporter gene can then be inserted into a cloning vector by restriction digest and ligation. Suitable cloning vectors for the assembly of transgenic constructs are those which provide for acceptable yields of DNA.
Suitable cloning vectors for the assembly of transgenic constructs are those which provide for acceptable yields of DNA. Any commercially available plasmid vector or phage that can carry a cDNA and which can be manipulated to contain a selection marker is suitable.
<Desc/Clms Page number 4>
The CaM-K-11 promoter is operably linked to the coding sequence of the APP encoding polynucleotide in a manner that will permit the required temporal and spatial expression of the polynucleotide. There may or may not be intervening sequences between the linked polynucleotide and the promoter, provided that the promoter directs expression of the APP encoding polynucleotide so linked to it. Methods of so linking regulatory sequences to cDNAs to facilitate their expression are widely known in the art.
Such methods include, for example, directly ligating the nucleic acid comprising the CaMK-II promoter to the coding region of the APP encoding polynucleotide. Additional nucleic acid sequences may be included that modulate expression in the required manner. Examples of additional sequences include enhancer elements, artificial intron and others. In addition the nucleotide sequence of the CaM-K-II promoter, or other regulatory sequence, may be modified to increase levels of expression. Such modifications can be achieved using, for example, site-directed mutagenesis methods well known in the art (see Sambrook et al, supra).
In addition to modifying the sequence of regulatory elements to enhance, or otherwise change, expression levels, the coding sequence of the APP encoding polynucleotide may be modified to enhance or otherwise affect expression levels. For example if the transgenic DNA is from a different species than the host, the codon usage of the transgenic DNA can be altered to match more closely that of the host. It is well known in the art that different organisms use the 64 coding and stop codons at different frequencies. Codons that are infrequently used in an organism are termed"rare codons". If a transgenic DNA includes a codon that is a rare codon in the host, expression levels may be severely reduced. One solution is to replace one or more rare codons in the transgenic DNA with codons that are frequently used in the host. Other modifications to the transgenic DNA sequence include modifying the polynucleotide sequence surrounding the start codon (the initiator methionin encoding codon) to make this more closely match the consensus"Kozak"sequence (A/G CCATGG, where the ATG in bold is the start codon; see for example Kozak, M (ref 24). In the transcribed mRNA molecule the Kozak sequence is believed to provide the optimal environment for initiation of translation of the polypeptide.
Preferably, prior to the introduction of the transgene into the host cell, the vector portions are removed by restriction enzyme digestion, for example by using restriction sites in the vector that flank the transgene. Thus the genetic material that is actually introduced into the host cell will preferably comprise the coding sequence of the APP encoding polynucleotide and the regulatory sequences to which it has been operably linked together with other potential components of the transgene, for example a reporter gene. An example of this technique is given in reference 25.
An inducible system such as described in Ref 26 may also be used, which has the
<Desc/Clms Page number 5>
advantage of regulating the gene expression (induction/repression). For example, the tetracycline-inducible system (Refs. 27,28) uses two constructs: a minimal promoter (PhCMV*-
1) fused to seven tetracyclic operator sequences and the cDNA in question; and a transgene containing the tetracycline-controlled trans-activator protein (tTA) coding sequence under the control of a promoter, for example taken from the following list: Human APP (ref. 9); rat neuron specific enolase (neurons) (ref. 29); human ss actin (ref. 30); human PDGFss (ref. 31); mouse Thy
1 (ref. 32); mouse Prion protein promoter (PrP) (ref. 33); Syrian hamster Prion protein promoter (ref. 34 and 35); rat synapsin 1 (brain) (ref. 36); human FMR1 (brain) (ref. 37); human neurofilament low (ref. 38), middle (brain) (ref. 39); NEX-1 (brain) (ref. 40); mouse APLP2 (brain) (ref. 41); rat alpha tubulin (ref. 42); mouse transferrin (ref. 43); mouse HMGCR (3hydroxy-3-methylglutaryl coenzyme A reductase, oligodendrocytes) (ref. 44), mouse myelin basic protein (ref. 45), mouse CaM-kinase-II promoter (ref. 21 and 22), human thy-l promoter (ref. 10), JC viral early region promoter (ref. 11); or human neurofilament NF-L transcriptional regulatory sequences (ref. 12). Each construct is used to generate a transgenic mouse. Crossing the two homozygous mice generates a double transgenic line which expresses the tTA according to the chosen promoter. This tTA induces expression of the cDNA by activating the PhCMV*- !, but only in the absence of tetracycline. In the presence of tetracycline there is only basal expression.
Generation of transgenic non-human mammals of the invention may be carried out conventionally, for example as described in W093/14200, W091/19810, W093/02189, W089/00689, W092/06187, EP0451700, W092/13069 and W089/06689.
There are a number of techniques that permit the introduction of genetic material, such as a transgene, into the germline. The most commonly used, and preferred protocol comprises direct injection of the transgene into the male pronucleus of the fertilised egg (Hogan et al. (25), resulting in the random integration into one locus of a varying number of copies, usually in a head to tail array (Costantini and Lacy (46) ). The injected eggs are then re-transferred into the uteri of pseudo-pregnant recipient mothers. Some of the resulting offspring may have one or several copies of the transgene integrated into their genomes, usually in one integration site. These "founder"animals are then bred to establish transgenic lines and to back-cross into the genetic background of choice. It is convenient to have the transgene insertion on both chromosomes (homozygosity) as this obviates the need for repeated genotyping in the course of routine mouse husbandry.
Alternatively, for the production of transgenic mice, transgenes can be introduced via embryonic stem (ES) cells, using electroporation, retroviral vectors or lipofection for gene transfer. This is followed by the random insertion into the genome of the pluripotent embryonic stem (ES) cells, followed by the production of chimeric mice and subsequent germline transmission. Transgenes
<Desc/Clms Page number 6>
of up to several hundred kilobases of rodentian DNA have been used to produce transgenic mice in this manner (for example Choi et al. (47); Strauss et al. (48) ). The latter approach can be tailored such that the transgene is inserted into a pre-determined locus (non-randomly, for example ROSA26 or HPRT) that supports ubiquitous as well as tissue specific expression of the transgene (Vivian et al. (49)).
In one aspect, the transgenic mammal is generated by introduction of the transgenic construct into an embryo, insertion of the embryo into a surrogate mother and allowing the embryo to develop to term.
The transgenic construct is prepared for transfer to the host animal by cleavage of vector containing the transgenic construct and purification of the DNA (ref. 25)
The transfer is carried out conventionally preferably using microinjection as described in detail in reference 25.
In an alternative aspect the parent transgenic non-human mammal is produced by introduction of the construct into embryonic stem cells by conventional methods such as calcium phosphate/DNA precipitation, direct injection or electroporation (ref. 50) followed by injection of the transformed cells into blastocytes and insertion of the resulting embryo into a surrogate mother as described above.
Transgenic animals may be identified by testing to ensure the required genotypic change has been effected. This may be done in any suitable fashion, for example by detecting the presence of the transgene by PCR with specific primers, or by southern blotting, preferably of tail DNA, with a specific probe.
Once the desired genotype has been confirmed, the transgenic animal line can be subjected to various tests to determine the phenotype. The tests involved in this phenotypic characterisation depend on what genotypic change has been effected, and may include, for example, morphological, biochemical and behavioural studies. The transgenic animals of the present invention demonstrate an increase in APP processing leading to increased amyloid levels and other APP cleavage products in the brain. In addition, they are likely to demonstrate cognitive defects.
This invention also includes any cells cultured from the transgenic non-human animal. The cells are cultured in-vitro. The genome of the cells can thus comprise the construct of the invention. The human APP polypeptide is typically expressed in such cells in an amount at least 2, preferably at least 5, for example 6,7, 8,9, and particularly preferably at least 1O. times greater than the amount of endogenous APP polypeptide that is expressed in the cells.
Cells cultured in-vitro from a transgenic animal may be prepared by any suitable method.
The cells are typically rodent and preferably mouse cells. Cultures of neuronal cells can therefore
<Desc/Clms Page number 7>
be provided, for example cultures of primary hippocampal cells. The cells may be used to introduce other genes of interest by any known method (including viral delivery).
The transgenic non-human mammal is preferably a rodent such as rat or mouse, more preferably a mouse.
The appropriate transgenic DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site (s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
The use of non-human animal models which overexpress or lack more than one gene can provide important insights into the interaction of different genetic loci in particular diseases, for example Alzheimers Disease. Consequently the interbreeding of the APP transgenic non-human animals of the present invention with non-human animal models which overexpress or underexpress a different transgene may produce alternative and potentially superior animal models of diseases such as Alzheimers. For example, the APP transgenic non-human animals of the present invention may be crossed with mice bearing a transgene comprising a nucleotide encoding the human aspartyl protease 2 protein (one example of such mice is described in the examples of this specification). In another aspect, the APP transgenic non-human animals of the present invention may be crossed with mice bearing a transgene comprising a nucleotide encoding the human presenilin protein. (such mice are described, for example, in W098/17782).
In each aspect, the second transgene may comprise a nucleotide encoding a wild type protein, or may comprise a nucleotide encoding a mutated protein. Preferred mutations in the presenilin transgene are A246E, M 146V and M146L.
The promoter of the second transgene may be any promoter that will lead to expression of the transgenic DNA in the transgenic non-human animal. The promoter may be, for example, Human APP (ref. 9); rat neuron specific enolase (neurons) (ref. 29); human ss actin (ref. 30); human PDGFss (ref. 31) ; mouse Thy 1 (ref. 32); mouse Prion protein promoter (PrP) (ref. 33); Syrian hamster Prion protein promoter (ref. 34 and 35); rat synapsin 1 (brain) (ref. 36); human FMRI (brain) (ref. 37); human neurofilament low (ref. 38), middle (brain) (ref. 39) ; NEX-1 (brain) (ref. 40); mouse APLP2 (brain) (ref. 41); rat alpha tubulin (ref. 42); mouse transferrin (ref. 43); mouse HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase, oligodendrocytes) (ref. 44), mouse myelin basic protein (ref. 45), mouse CaM-kinase-II promoter (ref. 21 and 22), human thy-1 promoter (ref. 10), JC viral early region promoter (ref. 11); or human neurofilament NF-L transcriptional regulatory sequences (ref. 12).
It is, however, preferable that both of the precursor transgenic non-human animal lines comprise transgenes which are operably linked to a neuronal specific promoter, for example the
<Desc/Clms Page number 8>
CamKII promoter or the Thy 1. This ensures that in the non-human animal produced by the cross, both transgenes are expressed in a neuronal specific manner. In a preferred embodiement, a non-human transgenic animal is generated by crossing the APP lines of the present invention with a non-human transgenic animal whose cells contain transgenic DNA encoding the human Aspartyl 2 Protease (asp2). Particularly preferred is when said Asp2 encoding transgenic DNA is operably linked to the CamKII promoter. In a further preferred embodiment, a non-human transgenic animal is generated by crossing the APP lines of the present invention with a nonhuman transgenic animal whose cells contain transgenic encoding the human Presenilin 1 protein (PS 1). Particularly preferred is when said PS 1 encoding transgenic DNA is operably linked to the human PDGFss promoter.
Such transgenic non-human animals containing more than one transgene wherein one of the transgenes comprises a nucleotide encoding the human APP protein operably linked to the CamKII promoter are also part of the invention, and may be used as described herein. The transgenic non-human animal or cells of the invention may be used to screen for drugs which inhibit deposit of Ass by administering test drug to the mammal or cell culture medium and observing changes in APP expression and processing, histopathology and/or behavioural changes. The invention extends to such method of screening.
Suitable techniques for making such observations are described in W093/14200.
A method of identifying a therapeutic agent for the treatment of a condition characterised by the deposition of amyloid plaques and decreased cognition can therefore be provided, comprising : administering to an animal of the invention a candidate test substance and determining whether the candidate substance (1) prevents or delays the onset of the condition or (ii) treats the condition.
Option (ii) may be tested by determining whether the candidate substance causes a decrease in any of the cellular or physiological changes caused by the condition. Such cellular or physiological changes may include changes in the deposition of amyloid plaques, or a decrease in cognition and awareness of the transgenic non-human mammal.
A method of identifying a therapeutic agent for the treatment of a condition characterised by deposition of amyloid plaques and decreased cognition can also be provided, comprising:
contacting a candidate substance with a cell of the invention, and - determining whether the candidate substance (i) prevents or delays the onset of cellular changes associated with the condition, or (ii) causes a decrease in any of the cellular changes caused by the condition (such as any of the cellular changes mentioned herein).
<Desc/Clms Page number 9>
Suitable candidate substances which may be tested in the above methods include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR grafted antibodies). Furthermore, combinatorial libraries, defined chemical identities, small molecules, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e. g. phage display libraries) may also be tested. The candidate substances may be chemical compounds. Batches of the candidate substances may be used in an initial screen of, for example, ten substances per reaction, and the substances of batches which show inhibition tested individually.
Agents which may reverse the phenotypic changes such as the deposition of amyloid plaques and a decrease in cognition seen in the transgenic animals of the invention may be tested in-vivo or in cells or tissue preparations in-vitro. Compounds can be tested using the assays and tests used to characterise the invention. For example, after administration of any potential therapeutic agent, the response of the transgenic animal may be assessed by, for example, looking for an improvement in cognition. Methods for screening potential therapeutic agents using cell lines or animals are established. ELISA or Homogenous Time Resolved Fuorescence (HTRF) methodologies can be used.
Agents identified in the screening methods of the invention may be used to prevent or treat the diseases discussed above, in particular Alzheimers Disease. The condition of a patient suffering from such a disease can therefore be improved by administration of such a product. The formulation of the product for use in preventing or treating the disease will depend upon factors such as the nature of the agent identified and the disease to be prevented or treated. Typically the agent is formulated for use with a pharmaceutically acceptable carrier or diluent. For example it may be formulated for intracranial, parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration. A physician will be able to determine the required route of administration for each particular patient. The pharmaceutical carrier or diluent may be, for example, an isotonic solution.
The dose of product may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A suitable dose may however be from 0. 1 to 100 mglkg body weight such as 1 to 40 mg/kg body weight. Again, a physician will be able to determine the required route of administration and dosage for any particular patient.
The construct, cells or therapeutic agents of the invention may be present in a substantially isolated form. It will be understood that they may be mixed with carriers or diluents which will not interfere with their intended purpose and still be regarded as substantially isolated.
Thus the construct, cell or therapeutic agent of the invention may also be in a substantially
<Desc/Clms Page number 10>
purified form, in which case it will generally comprise more than 90%, e. g. more 95%, 98% or 99%, by weight of the relevant preparation.
Examples Generation of transgenic mice expressing APPV46F
The APPV46F cDNA, with the sequence referred to in Ref33, was prepared by site directed mutagenesis of the 695 isoform of APP. To generate the APPV46F mis-expression transgenes, the APPV46F cDNA was cloned into the vector pCamKIRESbgal. This vector contains the mouse calcium-calmodulin-dependent kinase IIa (CamKIIa) promoter, which has previously been shown to direct transgene expression to both the hippocampus and neocortex of
the mouse forebrain (Ref 36). The promoter is isolated in the manner described in ref 36 (see in particular reference note 20 or ref 36). Then, an 8. 5kb Sail promoter fragment was isolated by restriction digestion. This was ligated into Arm3 vector (a derivative ofpBluescript with the sites indicated flanking the SacI-KpnI pBluescript polylinker) digested with XhoI and Sail. This generated Arm3-CamKII (the 5'Sail site is destroyed). The 5Isolate form AS210S (a derivative of Plasmid AS210 (obtained from Stem Cell Sciences, Melbourne) contains the IRES-bgalintro-poly fragment as an XbaI-XhoI restriction fragment. The Xbal site was converted to a
Sail site (to create AS21 OS), and the resultant SalI/XhoI fragment containing the IRES-bgal- intro-poly cassette was ligated into the SalI site of Arm3-CamKII to generate CamKII-IRESbgal. This contains unique NotI and SaIl sites for the insertion of cDNAs. In the resulting vector, the promoter is upstream of a cassette containing the picornaviral internal ribosome-entry site
(IRES) (Ref 52) and the gene for beta-galactosidase and SV40 transcription termination signals.
The APP V46F cDNA was then inserted between the CamKII promoter and the IRES using the NotI and Sail sites. Transcription which initiates at the CamKIIapromoter capsite and terminates at the SV40 polyadenylation signals therefore results in a dicistronic message encoding APPV46F and beta-galactosidase proteins. The latter can be easily detected to confirm that transgene expression has taken place. The inclusion of a beta-galactosidase reporter gene in the construct enables simple, accurate and sensitive detection of cellular sites of transgene expression. This cloning process is shown schematically in figure 1.
The above described construct is used to generate transgenic mice by the following procedures: The construct is prepared and purified.
Female mice are induced to superovulate and embryos are recovered.
DNA is microinjected into the pronucleus of embryos.
<Desc/Clms Page number 11>
Embryos are transferred into pseudopregnant mice (female mice previously paired with vasectomised males).
Embryos are allowed to develop normally and mice are born.
Founder mice are identified by Southern blot and PCR and bred on.
Suitable mice lines are as follows; Donor mice (embryos for pronucleus injection): [C57Bl/6 x CBA] F2 hybrid Acceptor mice: [C57Bl/6 x CBA] F1 hybrid Mice for further breeding: C57Bl/6 Crossbreeding of transgenic mice to generate carriers of two transgenes The transgenic mice expressing APP and the further desired transgene, for example aspartyl 2 protease, or presenilin which may be wild type presenilin, or may contain a mutation such as M146V, M671L or M146V, are crossbred and the offspring genotyped to select those with both of the transgenes. Preferably, both transgenes are under the control of the CamKII promoter. If the APP transgene is'a'and the second transgene is'b', then the following mating pattern is possible from heterozygous parents with two independently segregating genes:
alleles b a ab a- - b One in four offspring would be a double overexpressor, two in four would be single overexpressors (one for each transgene) and one in four offspring would be a wild type mouse.
This cross can be used to calculate the number of parents required to produce an experimental cohort of double overexpressors.
Generation of transgenic mice expressing ASP2
The ASP2 cDNA, with the sequence referred to in Ref 53 was prepared according to convention techniques. To generate the Asp2 mis-expression transgenes, the Asp2 cDNA was cloned into the vector pCamKIRESbgal, prepared as above.
The above described construct is used to generate transgenic mice by the following procedures: The construct is prepared and purified.
Female mice are induced to superovulate and embryos are recovered.
DNA is microinjected into the pronucleus of embryos.
<Desc/Clms Page number 12>
Embryos are transferred into pseudopregnant mice (female mice previously paired with vasectomised males).
Embryos are allowed to develop normally and mice are born.
Founder mice are identified by Southern blot and PCR and bred on.
Suitable mice lines are as follows; Donor mice (embryos for pronucleus injection): [C57Bl/6 x CBA] F1 hybrid Acceptor mice: [C57BI/6 x CBA]FI hybrid Mice for further breeding: C57BI/6 Screening of drugs using transgenic mice
The transgenic mice described above may be used to screen for potential activity of test drugs in the treatment of Alzheimer's disease and other neurodegenerative disorders.
APP expression and processing may be examined using detection of mRNA by Northern blots and detection of polypeptides using polyclonal and monoclonal antibodies that are specific to the terminal regions of the target peptides.
Histopathological observations may be made using immunohistological techniques to permit identification of amyloid plaques and related deposits such as hyperphosphorylated tau and in situ hybridisation using labelled probes to target mRNA.
Analyses of mouse brain
Animals are culled by overdose of anaesthetic. Brains are removed and hemisected down the midline. The halves are placed in either 10% formal saline or snap frozen.
Extraction of Ass and APP from mouse brain for immunoassay
Snap frozen half brains are weighed and then homogenised using a Polytron homogeniser on maximum speed for 30 seconds. Homogenates are prepared at 20% wt/vol in 50mM TrisHCI, 150mM NaCl, pH 8 with complete TM protease inhibitor (Boehringer Mannheim) added on the day according to the manufacturer's instructions.. Homogenates are then diluted with an equal volume of 50mM Tris-HCI, 150mM NaCI pH 8 containing 1% Nonidet P40 (10% solution, Pierce), 1 % deoxycholate, 0.4% sodium dodecyl sulphate and complete TM (as above).
Homogenates are then sonicated in a water bath sonicator for 45 minutes and then boiled for 10 minutes in a large beaker of water. The homogenates are then transferred to 1. 5ml Eppendorf tubes and centrifuged at 12000 rpm for 10 minutes. The supernatants are removed and stored in aliquots at-20 C.
<Desc/Clms Page number 13>
Immunocytochemical Assessment of Brains from Transgenic Mice
Hemisected mouse brain, stored in formal saline, is embedded in paraffin wax and cut into 10 u. m sections on a microtome before mounting onto gelatin subbed slides.
For immunocytochemistry, sections are dewaxed and rehydrated by standard techniques.
Sections being assessed for Ap or APP content are treated with 80% formic acid after rehydration. For other sections, boiling for 10 minutes in 0. 1M citrate buffer in a microwave oven enhances immunoreactivity. Endogenous peroxidase is blocked by incubating with hydrogen peroxide (0.3% in phosphate buffered saline for 30 minutes). Primary antibodies for Ass (lE8 - monoclonal to Ass 13-27; 0210- monoclonal to ABeta 33-40; 20gel0 and 5G5monoclonals to Ap 35-42, APP (22Cll - Weidemann et al, 1989), glial fibrillary acidic protein (anti-GFAP, Boehringer Mannheim), neuronal markers (synaptophysin, MAP-2, choline acetyl transferase-Boehringer Mannheim) and normal and hyperphosphorylated tau (Innogenetics) are incubated with the sections overnight at 4 C. Sections are visualised using DAB (Vector Labs) and after dehydration are mounted in DPX aqueous mountant.
Protein Assay
Mouse brain homogenates are assayed for protein before gel electrophoresis to ensure equal protein loading between samples for comparison of expression levels. The proteins are measured by the Bradford dye-binding procedure (Ref 28) using Bio-Rad (Herts, UK) dye reagent concentrate. The assay is carried out in a 96 well plate with the absorbance read at 595nm using a Spectramax plate reader with software to analyse the results. As various reagents, particularly detergents, interfere with the Bradford assay calibrations are carried out in the appropriate sample vehicle.
SDS-PAGE
Proteins are fractionated using a Novex mini-gel system (R & D Systems Europe Ltd, Oxon, UK). An equal amount of protein is loaded for comparison of APP expression levels between animals. Samples are diluted in 2x reducing sample buffer containing 0. IM Tris pH6.8, 10% sodium dodecyl sulphate (SDS), 0. 1 % bromophenol blue in glycerol and 50% ss- mercaptoethanol. The proteins are separated on a 6% Tris-glycine polyacrylamide gel containing SDS (Ref. 29) for 90 minutes at 125 volts. Protein standards are included of known molecular weight (Sigma) as well as a secreted APP standard (Pichia expressed, see Ref 32).
<Desc/Clms Page number 14>
Western Blot Analysis
After SDS-PAGE the gels are washed for 5 minutes in transfer buffer containing 2.5mM Tris, 19. 2mM glycine, 20% methanol at pH 8.3. The proteins are transferred from the gel onto 0.45um nitrocellulose membrane (Schleicher & Schuell) using a Bio-rad semi-dry system for 2 hours at 0. 8mNcm2. After transfer the proteins are visualised on the membrane by staining with a 10% solution of Ponceau S (Sigma) for 2 minutes. This is detained by rinsing with distilled water.
The membrane is blocked in phosphate buffered saline (PBS) containing 10% dried milk powder for at least 1 hour at room temperature. W02, monoclonal antibody raised against human Ass 1-16, IS incubated at 1ug/ml in PBS overnight at 40C. This is followed by three 10 minute washes in PBS. Secondary antibody is then added, this was anti-mouse horseradish peroxidase (Amersham NA931) at 1/3000 dilution in PBS containing 4% bovine serum albumin and 0. 1 % Tween 20 incubated for 1 hour at room temperature. PBS washes are repeated as above and then the membrane transferred to a clean dish for addition of enhanced chemiluminescence substrate (Amersham RPN2106). The immunoreactive bands are detected using Hyperfilm-ECL (Amersham) which was developed using an automated processor (X-OGraph Compact X4). APP bands are scanned using a Fluor-S Multilmager (Bio-rad) linked to a computer with software for processing data.
Determination of the Concentration of Ap 140 and 1-42 by Immunoassay
For the immunoassay of Ap 1-40, plates (Gibco BRL, flat bottom 96 well plate, catalogue # 1-67008-A) are coated (overnight at 4 C) with 2F12 capture antibody, raised to Ass 1-16 peptide, at 0. 8/lg/ml m PBS. After coating, antibody solution is aspirated and plates blocked by incubating for 60 minutes at 37 C with 1% gelatine v/v (Amersham RPN416) in assay buffer (50mM Tris HCI, 150mM NaCl, 0.5% bovine gamma globulins, 0.05% Tween 20, pH 7.4, passed through a 0.2um filter before use). Following blocking, plates are washed 4 x 250ul with phosphate buffered saline with Tween 20 (Sigma Cat No P3563). Samples of mouse brain extract prepared as described above are added to the plates together with the detection antibody, biotinylated G21 0 (1/lg/ml m assay buffer) raised to an Ap 40 C-terminal peptide (Ref 30). The 2F 12 coated plate containing brain extract and 150ul of detection antibody is incubated overnight at 4 C. Plates are subsequently washed (4 x 250ul) with phosphate buffered saline with Tween 20.
Quantitation of peptide-antibody complexation is achieved by the binding of strepatavidin-Europium. To each well is added 200ul streptavidin-Europium (Wallac, Catalogue # 1244-360) diluted 1: 500 in 0.5% BSA, 0.05% Globulin, 0.01% Tween 20, 20uM DTPA
<Desc/Clms Page number 15>
(Sigma D 6518) in Tris buffered saline pH 7.4. Plates are incubated at room temperature for 60 minutes before washing with phosphate buffered saline. Finally, 200ul of enhancer solution (Wallac, Catalogue # 1244-105) is added to each well and the plate shaken for 5 minutes at room temperature before measurement of emission by time-resolved fluorescence on a Wallac 1234 Delfia Fluorometer.
For the determination of Ap 1-42, plates are coated with the monoclonal antibody 5G5 (1g/ml in phosphate buffered saline) raised to the Ap 35-42 peptide. Detection is with biotin- 6E10 antibody (Senetek PLC). All other details are exactly as for Ass 1-40 determination.
Ap 1-40 and 1-42 (California Peptide Research Inc) are used for the construction of standard curves. Peptides are dissolved in dimethyl sulphoxide and diluted in appropriate brain extract buffer. Standards of Ass 1-40 and 1-42 are assayed with each batch of mouse brain extract. The concentration of Ass 1-40 and 1-42 is calculated by reference to the immunoassay signal produced by known concentrations of peptide.
Determination of the Concentration of full length and alpha-secretase cleaved APP by Immunoassay
For the immunoassay of full length plus alpha-secretase cleaved APP (FL+sAPPa),
plates (Gibco BRL, flat bottom 96 well plate, catalogue # 1-67008-A) are coated (overnight at 4 C) with W02 capture antibody (Ref37), raised to Ass 1-16 peptide, at 2. 7f. lg/ml in PBS. After coating, antibody solution is aspirated and plates blocked by incubating for 60 minutes at 37 C with 1% gelatine v/v (Amersham RPN416) in assay buffer (50mM Tris HCl, 150mM NaCI, 0.5% bovine gamma globulins, 0.05% Tween 20, pH 7.4, passed through a 0. 2um filter before use). Following blocking, plates are washed 4 x 250ul with phosphate buffered saline with Tween 20 (Sigma Cat No P3563). Samples of mouse brain extract prepared as described above are added to the plates together with the detection antibody, a polyclonal raised to APP (Ref 31).
The 2F12 coated plate containing brain extract and 150ul of detection antibody is incubated overnight at 4 C. Plates are subsequently washed (4 x 250ul) with phosphate buffered saline with Tween 20.
Quantitation of peptide-antibody complexation is achieved by the binding of Europiumantirabbit IgG (Wallac) diluted 1: 500 in 0.5% BSA, 0.05% Globulin, 0. 01% Tween 20, 20uM DTPA (Sigma D 6518) in Tris buffered saline pH 7.4. Plates are incubated at room temperature for 60 minutes before washing with phosphate buffered saline. Finally, 200ul of enhancer solution (Wallac, Catalogue # 1244-105) is added to each well and the plate shaken for 5 minutes at room temperature before measurement of emission by time-resolved fluorescence on a Wallac 1234 Delfia Fluorometer.
<Desc/Clms Page number 16>
Alpha-secretase cleaved secreted APP prepared from Pichia pasioris (see Ref 32) is used for the construction of a standard curve. The concentration ofFL+sAPPa (this antibody format does not distinguish between full length and alpha-cleaved APP) is calculated by reference to the immunoassay signal produced by known concentrations of peptide.
Observation of behavioural changes
Observation of behavioural changes may employ conventional tests used to assess learning and memory deficits (Ref 54).
References 1. Kang et al., Nature 325: 733-736, (1987).
2. Ponte et al., Nature 331: 525-527 (1998).
3. Kitaguchi et al., Nature 331: 530-532, (1988).
4. Sandbrink, et al., J. Biol. Chem. 269: 1510-1517, (1994).
5. Dyrks T. , Weidemann A. , Multhaup G., Salbaum J. M. , Lemaire H.-G., Kang J., MüllerHill B. , Masters C. L., Beyreuther K., EMBO J. 7, 949-957, (1988).
6. Dyrks T., Dyrks E., Mönning U., Urmoneit B., Turner J., Beyreuther K. FEBS Letters
335,89-93, (1993).
7. Haass C. , Hung A. Y. , Schlossmacher M. G. , Teplow D. B. , Selkoe D. J. J. Biol. Chem., 268, 3021-3024, (1993).
8. Suzuki N.; Cheung T. T.; Cat X. D.; Odaka A.; Otvos L. Jr.; Eckman C.; Golde T. E.,
Younkin S. G. Science 264,1336-1340, (1994).
9. Wirak D. O., et al Science 253,323-325, (1991).
10. Kawabata S. Nature 354 476-478, (1991).
11. Sandhu F. A. J. Biol. Chem. , 266 21331-21334, (1991).
12. = 15.
13. Greenberg B. D. et al., Neurobiology of Aging M2 153-171, (1996).
14. Games et al., Nature 373, 523-527, (1995).
15. Nalbantoglu et al., Nature 387: 500-505, (1997).
16. Hsiao et al., Science 274,99-103, (1996) 17. Sturchler-Pierrat et al., Proc. Natl. Acad. Sci. USA 94: 13287-13292, (1997).
18. Duff, Trend Neurosci. 20: 279-80, (1997) 19. Lichtenthaler et al., Neurobiology of Aging 17 (4) supp, s130-s131 abstract 524, (1996).
20. Lichtenthaler et al., Biochemistry 36: 15396-15403, (1997)
<Desc/Clms Page number 17>
21. Mayford et al. Science 274 (5293) 1678-1693 (1996) 22. Tang, Y-P et al., Nature 1999, 401, 63-69 23. Maniatis et al.,'Molecular Cloning, a Laboratory Manual', Cold Spring Harbor
Laboratory, Cold Spring Harbor (1989).
24. Kozak et al.., Nucleic Acids Res (1984) 12 (9) : 3873-3893 25. Hogan et al.,'Manipulating the mouse embryo', Cold Spring Harbor Laboratory, Cold
Spring Harbor (1994).
26. Rossi and Blau, Current Opinion in Biotechnology, 451-456 (1998).
27. Baron et al., Nucl. Acids Res. 23 (17) 3605-6 (1995).
28. Furth et al., Proc. Natl. Acad. , Sci. , USA 91,9302-9306 (1994).
29. Forss-Petter et al., Neuron 5 ; 197, (1990).
30. Ray et al., Genes and Development 5 ; 2265-2273 (1991).
31. Sasahara et al., Cell 64 ; 217-227 (1991).
32. Ingraham et al., Mol. Cell. Biol. 6 (8) 2923-31 (1986).
33. M. Fischer et al., EMBO J. 15 (6) 1255-64, (1996).
34. Scott et al., Prot. Sci. i, 986-997 (1992).
35. Scott et al, Cell 59,847-857 (1989) 36. Howland et al., Neurobiol. Aging 16 (4) 685-99, (1995).
37. Hergersberg et al., Hum. Mol. Genet. 4 (3) 359-66 (1995).
38. Thomas et al., J. Virol. 68 (11) 7099-107 (1994).
39. Tu et al., J. Cell. Biol. 129 (6) 1629-40 (1995).
40. Bartholoma et al., Mech. Dev. 48 (3), 217-8 (1994).
41. Kock et al., J. Biol. Chem. 270 (43) 25475-80 (1995).
42. Gloster et al., J. Neurosci. 14 (12), 7319-30 (1994).
43. Thiesen et al., Mol. Cell. Biol. 13 (12) 7666-76 (1993).
44. Duhamel-Clerin et al., Glia 11 (1) 35-46 (1994).
45. Readhead et al., Cell 48; 703-712 (1987).
46. Constantini et al. Nature 294,92, 1981 47. Choi et al. Nature Genet. 4,117-123 (1993) 48. Stauss et al. Science 259,1904-07 (1993) 49. Vivian et al. BioTechniques 27,154-162 (1999) 50.'Teratocarcinomas and embryonic stem cells, a practical approach'ed. E. J. Robertson,
IRL Press, (1987).
52. Mountford P, et al. Proc Natl Acad Sci USA 1994,91 (10): 4303-7 53. Hussein et al Molecular and Cellular Neuroscence (1999) 14 pp 419-427 54. Rogers DC et al, Mamm Genome. (1997) Oct; 8 (10) : 711-3.
Claims (13)
- Claims 1. A recombmant DNA construct comprising a coding sequence encoding human APP with a mutation selected from V46F, V461, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N, and V46Q and a brain-specific calcium calmodulin kinase promoter sequence which is operably linked to the coding sequence.
- 2. A transgenic non-human animal whose genome incorporates a polynucleotide comprising a coding sequence which encodes the human APP protein with a mutation selected from V46F, V461, V46G, V46Y, V46L, V46A, V46P, V46W, V46M, V46S, V46T, V46N, and V46Q wherein said coding sequence is operably linked to a brain- specific calcium calmodulin kinase II promoter.
- 3. A transgenic non-human animal according to claim 2 wherein the said brain cells are cells of the hippocampus, cerebellum or cortex.
- 4. A transgenic non-human animal according to claim 2 or 3 which is a rodent.
- 5. A transgenic non-human animal according to claim 4 which is a mouse.
- 6. A transgenic non-human animal cell whose genome incorporates a nucleotide comprising a coding sequence which encodes the human APP protein and a brain-specific calcium calmodulin kinase II promoter sequence which is operably linked to the coding sequence.
- 7. A cell according to claim 6 which is a rodent cell.
- 8. A cell according to claim 7 which is a mouse cell.
- 9. A method of producing a transgenic non-human animal as defined in claim 2, which method comprises : (a) introducing a construct as defined in claim 1 into a cell or embryo; and (b) generating a said animal from said cell or embryo.
- 10. A method according to claim 9 wherein the construct is injected into the pronucleus of a fertilized oocyte of a non-human animal.
- 11. A method according to claim 9 or 10 wherein the founder animals that are obtained are bred.
- 12. A method of evaluating a therapeutic agent for use in the treatment of alzheimer disease, which method comprises: i) administering the said agent to a transgenic non-human animal as defined in any of claims 2 to 5, or a transgenic non-human animal cell as defined in any of claims 6 to 8, and ii) evaluating the effect of the said agent on the transgenic non-human animal or said non-human transgenic animal cell.
- 13. A kit for screening agents for use in the treatment of alzheimers disease, which kit comprises a transgenic non-human animal cell as defined in any one of claims 6 to 8 and a means<Desc/Clms Page number 19>for determining whether a test agent inhibits cellular changes associated with APP expression in said cell.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0120344A GB0120344D0 (en) | 2001-08-21 | 2001-08-21 | Compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0219386D0 GB0219386D0 (en) | 2002-09-25 |
GB2380196A true GB2380196A (en) | 2003-04-02 |
Family
ID=9920762
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0120344A Ceased GB0120344D0 (en) | 2001-08-21 | 2001-08-21 | Compounds |
GB0219386A Withdrawn GB2380196A (en) | 2001-08-21 | 2002-08-20 | Transgenic animals with mutant human amyloid precursor protein sequences |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0120344A Ceased GB0120344D0 (en) | 2001-08-21 | 2001-08-21 | Compounds |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB0120344D0 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960117B2 (en) | 2006-03-16 | 2011-06-14 | Vib Vzw | Promoter mutations that increase amyloid precursor protein expression |
WO2013041577A1 (en) | 2011-09-20 | 2013-03-28 | Vib Vzw | Methods for the diagnosis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003643A2 (en) * | 1996-07-22 | 1998-01-29 | Smithkline Beecham Pharma Gmbh | Transgenic animals with mutant human app or a4ct sequences |
WO1998058060A1 (en) * | 1997-06-18 | 1998-12-23 | Smithkline Beecham Pharma Gmbh | Human app or a4ct sequences encoding the mutation 145f |
US6184435B1 (en) * | 1991-10-03 | 2001-02-06 | Advanced Research And Technology Institute | Transgenic mouse expressing APP770-V717F |
US6262335B1 (en) * | 1994-01-27 | 2001-07-17 | Johns Hopkins University | Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 |
-
2001
- 2001-08-21 GB GB0120344A patent/GB0120344D0/en not_active Ceased
-
2002
- 2002-08-20 GB GB0219386A patent/GB2380196A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184435B1 (en) * | 1991-10-03 | 2001-02-06 | Advanced Research And Technology Institute | Transgenic mouse expressing APP770-V717F |
US6262335B1 (en) * | 1994-01-27 | 2001-07-17 | Johns Hopkins University | Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 |
WO1998003643A2 (en) * | 1996-07-22 | 1998-01-29 | Smithkline Beecham Pharma Gmbh | Transgenic animals with mutant human app or a4ct sequences |
WO1998058060A1 (en) * | 1997-06-18 | 1998-12-23 | Smithkline Beecham Pharma Gmbh | Human app or a4ct sequences encoding the mutation 145f |
Non-Patent Citations (2)
Title |
---|
Learning Memory; Vol 5, pp 429-445 (1998). Kojima et al. "Higher seizure susceptibility... * |
Proc Natl Acad Sci USA; Vol 98, pp 3549-3554 (2001). Hern¾ndez-S¾nchez et al. "Mice transgenically overexpressing sulfonurea receptor 1 in forebrain..." * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960117B2 (en) | 2006-03-16 | 2011-06-14 | Vib Vzw | Promoter mutations that increase amyloid precursor protein expression |
WO2013041577A1 (en) | 2011-09-20 | 2013-03-28 | Vib Vzw | Methods for the diagnosis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration |
Also Published As
Publication number | Publication date |
---|---|
GB0219386D0 (en) | 2002-09-25 |
GB0120344D0 (en) | 2001-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6262335B1 (en) | Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 | |
Flood et al. | FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction | |
US5877399A (en) | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease | |
EP0653154A2 (en) | Transgenic animal for alzheimer's disease | |
EP0451700A1 (en) | Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease | |
WO1997048792A9 (en) | Transgenic non-human mammals with progressive neurologic disease | |
JP2001517065A (en) | Methods for identifying therapeutic agents for Alzheimer's disease using transgenic animal models | |
RU2266002C2 (en) | Method for obtaining animal being distinct against a man with a certain mutated gene, method for testing substance to be applied for treating alzheimer's disease (variants), plasmid (variants), method for obtaining primary cell culture or subcultivated cell | |
US20030148356A1 (en) | Novel APP mutation associated with an unusual Alzheimer's disease pathology | |
US20080301827A1 (en) | Transgenic animal model of neurodegenerative disorders | |
US7247766B2 (en) | Double transgenic mice overexressing human beta secretase and human APP-London | |
CA2407847C (en) | Transgenic animal model of neurodegenerative disorders | |
GB2380196A (en) | Transgenic animals with mutant human amyloid precursor protein sequences | |
EP1285578B1 (en) | Transgenic animal model of Alzheimer's disease | |
EP1027433B1 (en) | Human app or a4ct sequences encoding the mutation i45f | |
WO2008066734A2 (en) | Transgenic mammals modified bri protein expression | |
JP5046413B2 (en) | Targeted recombinant non-human mammal with human FAD presenilin mutation and reproductive progeny | |
KR100699453B1 (en) | Transgenic animals as models for neurodegenerative disease | |
EP1340424B1 (en) | Double transgenic, non-human mammalian animal model for Alzheimer's disease | |
CA2814737C (en) | Use of an a.beta.42 peptide to reduce a cognitive deficit in a subject | |
WO2006134342A2 (en) | Mutants of human app and their use for the production of transgenic animals | |
Von Koch | Molecular analysis of a homologue of the mouse beta-amyloid precursor protein, APLP2: Isolation of APLP2cDNA, characterization of the APLP2 gene promoter and gene targeting of APLP2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |